A systematic review from the Hunter Medical Research Institute (HMRI) has raised concerns about the nutritional status of patients using GLP-1 medications, such as Ozempic, for weight loss. These drugs, approved by the FDA for Type 2 diabetes, have seen increased demand due to their effectiveness for weight management. However, as researchers noted, many clinical trials do not adequately monitor dietary changes or nutrient intake among users.
Read More
One significant finding in the review is the risk of vitamin deficiencies, including rare cases of scurvy, which stems from a lack of vitamin C. Scurvy is characterized by symptoms such as anemia, loose teeth, bruising, swollen gums, and slow healing of wounds. Although these cases appear uncommon, they underline a notable oversight in current research concerning the long-term health effects of GLP-1 medications.
The researchers emphasize that GLP-1 users should not stop their medication; rather, there is a pressing need for healthcare providers to monitor their patients' diets more closely. To ensure that even smaller meals remain nutritionally adequate, doctors are encouraged to perform detailed dietary assessments in future clinical trials.
Moreover, symptoms of nutrient deficiencies—like fatigue and irritability—can mimic the common side effects of GLP-1 medications, complicating early detection of potential problems. Beyond vitamin C, deficiencies in iron and certain B vitamins could also pose health risks, though such complications are noted to be rare.
Experts recommend that patients worry about their nutritional health should collaborate with registered dietitians and consider screening for deficiencies before beginning GLP-1 treatment. In summary, while effective for weight loss, long-term success with GLP-1 medications hinges on vigilant nutrition management.